H
HighLife
Development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation
About HighLife
HighLife SAS is a medtech company specializing in the development of a unique transcatheter mitral valve replacement (TMVR) system designed to treat patients suffering from mitral regurgitation. The company's core product, the HighLife Mitral Valve Replacement System, consists of a valve prosthesis and a ring-shaped Sub Annular Implant (SAI). This system is engineered to self-center and align itself upon delivery, ensuring an easy and safe implantation process. HighLife's TMVR system is versatile, covering a wide range of mitral valve regurgitation patients with its adaptable design, suitable for native annuli with a largest axis ranging from 35 mm to 50 mm. HighLife operates in the medical technology market, primarily serving healthcare providers and patients in need of advanced cardiac care solutions. The company's business model revolves around the development and eventual commercialization of its TMVR system, aiming to generate revenue through product sales and potentially licensing agreements once regulatory approvals are obtained. Keywords: TMVR, mitral regurgitation, medtech, valve prosthesis, Sub Annular Implant, self-centering, self-aligning, cardiac care, healthcare providers, investigational device.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Morzine, France
- Employees
- 95
- Open positions
- None listed
- Dealroom signal
- 89.2/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Developer Tools, Cardiology and cardiovascular, Patient Care, Hard Tech, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning HighLife.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES CEquity / VC | Dec 2020 | $0 | — | Undisclosed | — |
| SERIES B✓Equity / VC | Jan 2019 | $35M | $141M | Sectoral Asset Management · Sofinnova Partners · U.S. Venture Partners · Andera Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for HighLife is 1.9K monthly website visits, up 58.3% over the last three months. HighLife's team grew 30.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Sofinnova Partners
LivaNova- GBGeorg Börtlein
Sectoral Asset Management
U.S. Venture Partners
Andera Partners
Other known investors1 additional known investor
VI Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HighLife on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HighLife’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.